Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (121-130 of 190) with videos related to

Pageof 19
Sort By:
Arthritis Care & Research|June 18, 2019
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized StudyLeonard H Calabrese, Carlos Abud-Mendoza, Stephen M Lindsey, et al.
Rheumatology and Therapy|March 18, 2024
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARERoy Fleischmann, Ricardo Blanco, Filip Van den Bosch, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb studyMark C Genovese, Roy Fleischmann, Daniel Furst, et al.
RMD Open|July 6, 2021
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinibKurt de Vlam, Alexis Ogdie, Andrew G Bushmakin, et al.
The Journal of Rheumatology|January 30, 2010
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trialsRonald F van Vollenhoven, Paul Emery, Clifton O Bingham, et al.
Arthritis Research & Therapy|September 10, 2020
Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trialsMark C Genovese, Gerd R Burmester, Owen Hagino, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trialMark C Genovese, Roy Fleischmann, Bernard Combe, et al.
Lancet (London, England)|October 31, 2013
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trialJosef S Smolen, Paul Emery, Roy Fleischmann, et al.
Arthritis Care & Research|May 11, 2011
Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexateWilliam Rigby, Gianfranco Ferraccioli, Maria Greenwald, et al.
Arthritis Care & Research|June 25, 2019
Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus MethotrexateRoy Fleischmann, Tsutomu Takeuchi, Michael Schiff, et al.
Pageof 19

Showing results (121-130 of 190) with videos related to

Sort By:
Pageof 19
Arthritis Care & Research|June 18, 2019
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized StudyLeonard H Calabrese, Carlos Abud-Mendoza, Stephen M Lindsey, et al.
Rheumatology and Therapy|March 18, 2024
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARERoy Fleischmann, Ricardo Blanco, Filip Van den Bosch, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb studyMark C Genovese, Roy Fleischmann, Daniel Furst, et al.
RMD Open|July 6, 2021
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinibKurt de Vlam, Alexis Ogdie, Andrew G Bushmakin, et al.
The Journal of Rheumatology|January 30, 2010
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trialsRonald F van Vollenhoven, Paul Emery, Clifton O Bingham, et al.
Arthritis Research & Therapy|September 10, 2020
Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trialsMark C Genovese, Gerd R Burmester, Owen Hagino, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trialMark C Genovese, Roy Fleischmann, Bernard Combe, et al.
Lancet (London, England)|October 31, 2013
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trialJosef S Smolen, Paul Emery, Roy Fleischmann, et al.
Arthritis Care & Research|May 11, 2011
Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexateWilliam Rigby, Gianfranco Ferraccioli, Maria Greenwald, et al.
Arthritis Care & Research|June 25, 2019
Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus MethotrexateRoy Fleischmann, Tsutomu Takeuchi, Michael Schiff, et al.
Pageof 19